System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Norma C Gutiérrez, MD, PhD is an expert in Hematology at Centro de Investigación del Cáncer (Spain). As of October 2026, ScienceLeadR ranks Norma C Gutiérrez in the top 1% of experts worldwide for Paraproteinemias, Hemostatic Disorders and Multiple Myeloma. Norma C Gutiérrez has authored 389 publications, the most recent in 2026, and is an investigator in 27 clinical trials, 9 of them ongoing. SLR score: 1,551 (community average: 125). How the SLR is computed.

LeadR Profile

Norma C Gutiérrez, MD, PhD Centro de Investigación del Cáncer Spain
1 551 ScienceLeadR Reputation 1551

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Instituto de Investigación Biomédica de Salamanca

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 389

Citations

Citations: 16 497 1st author: 14 Last author: 53 Unique author: 0

Main journals

Blood 117
Leukemia 29
Haematologica 26
CL LYMPH MYELOM LEUK 25
Br J Haematol 16

Best Journals

J Clin Oncol 7
N Engl J Med 3
Cancer Cell 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma.
PMID 42641154 — safety, lymphoma, therapeutics, hematologic diseases		Blood Adv20260
Genomic and clinical landscape of RAS mutations in acute myeloid leukemia.
PMID 42886676 — hematology, leukemia, leukemia, myeloid, acute, leukemia, myeloid, mutation		Blood20260
Study of post-translational modifications of p53 in multiple myeloma.
PMID 42469225 — genes, multiple myeloma, genes, p53, phosphoric monoester hydrolases, protein processing, post-translational		Blood Cancer J20260
Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter study.
PMID 42459121 — genes, leukemia, leukemia, myeloid, acute, leukemia, myeloid, mutation, prognosis		Haematologica20260
Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.
PMID 42312383 — hematology, blood component removal, biomarkers, multiple myeloma		Br J Haematol20260

Clinical Studies 27

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 11
Phase 2 8
Phase 1 4
Phase 1/Phase 2 4

By status:

Completed 15
Active not recruiting 8
Recruiting 4

By type:

Interventional 27

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 4
multicentricup10 20

Main Topics

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
An Open Label Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring
2024-515457-21-00 — safety, therapeutics		Phase 1Recruiting2024
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab versus Lenalidomide plus Rituximab in patients With Relapsed Refractory (R R) Follicular Lymphoma Grade 1 to 3a or R R Marginal Zone Lymphoma
2023-504684-16-00 — lymphoma, follicular, safety, lymphoma, rituximab, lenalidomide, therapeutics		Phase 3Active not recruiting2021
Ph2 Study of MK 3475A in Hematologic Malignances in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Primary Mediastinal Large B cell Lymphoma
2024-510969-42-00 — cells, safety, hodgkin disease, lymphoma, b-cell, lymphoma, b-lymphocytes, pharmacokinetics, hyaluronoglucosaminidase		Phase 2Active not recruiting2024
A Phase 1 Study of JNJ 87801493 in Combination with CD3 T Cell Engagers
2023-505165-93-00 — cells, t-lymphocytes		Phase 1Active not recruiting2024
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE FL 2)
2023-506906-38-00 — lymphoma, follicular, safety, lymphoma, maintenance, drug-related side effects and adverse reactions, rituximab, lenalidomide, therapeutics, epcoritamab		Phase 3Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS